Урсодезоксихолевая кислота — многофункциональное средство в гастроэнтерологии
https://doi.org/10.52420/umj.24.5.116
EDN: YHXYLD
Аннотация
Введение. Синтезированная в 1950-е гг. урсодезоксихолевая кислота (УДХК) является высокоэффективным лекарственным средством гепатопротекции. Диапазон присущих ей плейотропных свойств хорошо изучен — это литолитический, гипохолестатический, иммуномодулирующий, антиапоптический и другие эффекты.
Цель работы — обсуждение фармакологических эффектов УДХК и результатов ее клинического применения при наиболее распространенных заболеваниях печени и желчного пузыря.
Материалы и методы. Для составления обзора использованы российские и зарубежные публикации, которые отбирались по принципу наилучшего соответствия целям работы и ключевым словам в электронных базах PubMed и eLibrary.ru, а также печатных источниках за период с 1981 г. по 2025 г.
Результаты и обсуждение. Мультитаргетное профилактическое и лечебное влияния УДХК включает в себя гепатопротективный эффект при гепатитах вирусной и алкогольной этиологии, улучшение клинико-лабораторных показателей при холестазе, снижение уровня холестерина при неалкогольной жировой болезни печени, литолитическое действие при билиарном сладже и желчнокаменной болезни, а также потенциальную способность к онкопревенции печени и всего пищеварительного тракта.
Заключение. УДХК обладает целым спектром положительных эффектов при гепатобилиарной патологии и некоторых других заболеваниях. Многокомпонентное действие наряду с высоким профилем безопасности позволяют широко использовать препарат в лечебной практике коморбидных пациентов гастроэнтерологического профиля.
Об авторе
Н. Б. Ковалёва
Уральский государственный медицинский университет
Россия
Конфликт интересов:
Россия
Ковалёва Нина Борисовна — кандидат медицинских наук, доцент кафедры поликлинической терапии, институт клинической медицины.
Екатеринбург
Конфликт интересов:
Нет
Список литературы
1. Nadinskaya MYu. Study of the use of ursodeoxycholic acid in hepatology from the standpoint of medicine based on scientific evidence. Consilium Medicum. 2003;5(6):318–322. (In Russ.). EDN: https://elibrary.ru/WJKIWD.
2. Guzior DV, Quinn RA. Review: Microbial transformations of human bile acids. Microbiome. 2021;9:140. DOI: https://doi.org/10.1186/s40168-021-01101-1.
3. Minushkin ON, Frolova AA, Shindina TS, Kropova OE, Mikhailova EV. Ursodeoxycholic acid in gastroenterological practice. Russian Medical Inquiry. 2018;2(1–1):18–22. (In Russ.). EDN: https://elibrary.ru/YUTAXA.
4. Cherkashina EA. Problems of diagnostics and treatment of gallbladder cholesterolosis. Ulyanovsk Medical and Biological Journal. 2015;(1):50–59. (In Russ.). EDN: https://elibrary.ru/TQAJJV.
5. Reichelson KL, Kondrashina EA, Pazenko EV. Ursodeoxycholic acid effect on the symptoms and life quality of patients with biliary sludge (AURA study). Russian Medical Journal. 2024;(6):26–30. (In Russ.). EDN: https://elibrary.ru/OBSMKI.
6. Ivashkin VT, Maevskaya MV, Pavlov ChS, Tikhonov IN, Shirokova YeN, Buyeverov AO, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: Clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24–42. (In Russ.). DOI: https://doi.org/10.22416/1382-4376-2016-26-2-24-42.
7. Yamamoto R, Tazuma S, Kanno K, Igarashi Y, Inui K, Ohara H, et al. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence: A randomized trial. Journal of Hepato-Biliary-Pancreatic Sciences. 2016;23(2):132–136. DOI: https://doi.org/10.1002/jhbp.316.
8. Plotnikova EYu, Sukhikh AS. Reduction of the risk of biliary lithiasis caused by various weight reduction options in obesity. Medical Council. 2024;(15):114–124. (In Russ.). DOI: https://doi.org/10.21518/ms2024-385.
9. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hübner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Digestive Diseases and Sciences. 1985;30:642–649. DOI: https://doi.org/10.1007/BF01308413.
10. Myazin RG. The place of ursodeoxycholic acid in the treatment of chronic viral hepatitis. Medical Council. 2017;(4):31–35. (In Russ.). DOI: https://doi.org/10.21518/2079-701X-2017-4-31-35.
11. Esaulenko EV, Nikitina OE, Dunaeva NV, Uskov AN, Mogilevets TL. Clinical experience with ursodeoxycholic acid (Urdoxa) in complex therapy of chronic viral hepatitis. Journal of Infectology. 2011;3(3):42–45. (In Russ.). EDN: https://elibrary.ru/OILERP.
12. Oreshko LS, Makhov VM, Balakhanov AA. Effect of therapy with the ursodeoxycholic acid drug Grinterol® on clinical and biochemical parameters of patients with hepatobiliary pathology. Results of an observational study in 2016–2017. Experimental and Clinical Gastroenterology. 2018;(6):150–159. (In Russ.). EDN: https://elibrary.ru/XZUCNF.
13. Poupon R, Serfaty L. Ursodeoxycholic acid in chronic hepatitis C. Gut. 2007;56(12):1652–1653. DOI: https://doi.org/10.1136/gut.2007.130484.
14. Kozko VN, Antsyferova NV, Solomennik AO, Kopeychenko YaI, Bondar AE, Sokhan AV. Clinical efficacy of ursodeoxycholic acid in patients with chronic hepatitis C. Scientific Bulletin of Belgorod State University. Series: Medicine. Pharmacy. 2013;(11):124–128. (In Russ.). EDN: https://elibrary.ru/RZRYID.
15. Sato S, Miyake T, Tobita H, Oshima N, Ishine J, Hanaoka T, et al. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World Journal of Gastroenterology. 2009;15(22):2782–2786. DOI: https://doi.org/10.3748/wjg.15.2782.
16. Reichelson KL, Prashnova MK. Ursodeoxycholic acid: Current guidelines and potential uses. Doctor.ru. 2015;(12):50–56. (In Russ.). EDN: https://elibrary.ru/UNJRUP.
17. Andreev DN, Dicheva DT, Kuznetsova EI, Maev IV. Non-alcoholic fatty liver disease: Treatment from the standpoint of evidence-based medicine. Lechashhij vrach. 2017;(2):45. (In Russ.). EDN: https://elibrary.ru/YHOFQD.
18. Sokol RJ, Devereaux M, Khandwala R, O’Brien K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology. 1993;17(5):869–881. PMID: https://pubmed.gov/8387948.
19. Lukivskaya O, Zavodnik L, Knas M, Buko V. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Advances in Medical Sciences. 2006;51:54–59. PMID: https://pubmed.gov/17357278.
20. Bettini R, Gorini M. Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyltoxic hepatopathy. La Clinica terapeutica. 2002;153(5):305–307. (In Italian). PMID: https://pubmed.gov/12510413.
21. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: Regulations of apoptosis by ursodeoxycholic acid. Journal of Lipid Research. 2009;50(9):1721–1734. DOI: https://doi.org/10.1194/jlr.R900011-JLR200.
22. Mayev IV, Yeremin MN, Karakozov AG, Kucheryavy YuA, Potekhin NP, Saydullayeva MG, et al. Dynamics of liver fibrogenesis at long-term monotherapy of chronic alcohol-induced hepatitis by ursodeoxycholic acid or essential phospholipids. Clinical Perspectives of Gastroenterology and Hepatology. 2013;(4):3–14. (In Russ.). EDN: https://elibrary.ru/QZGNTP.
23. Mayev IV, Eremin MN, Karakozov AG, Potekhin NP, Saidullayeva MG, Semiserin VA, et al. UDCA or essential phospholipid monotherapy in patients with alcoholic hepatitis. Vrach. 2013;(7):31–39. (In Russ.). EDN: https://elibrary.ru/RAEHRT.
24. Mayev IV, Kucheryavy YuA, Morozov SV, Stukova NYu. Effect of ursodeoxycholic acid drugs on blood biochemical parameters and results of liver elastography in patients with alcohol-induced liver cirrhosis. Clinical Perspectives of Gastroenterology, Hepatology. 2010;(4):43–48. (In Russ.). EDN: https://elibrary.ru/MTXGZT.
25. Shirokova EN, Kuznetsova EL, Maevskaya MV, Pavlov CS, Zolotarevskiy VB, Ivashkin VT. Efficiency of ursodeoxycholic acid in the treatment of patients with cholestatic alcoholic liver disease and primary biliary cirrhosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2007;17(3):52–59. (In Russ.). EDN: https://elibrary.ru/IBTVWN.
26. Eremina EYu. Alcoholic liver disease. Part 2. The Russian Archives of Internal Medicine. 2013;(1):60–63. (In Russ.). EDN: https://elibrary.ru/RPORBP.
27. Pelletier G, Roulat D, Davion T, Mastian C, Causse X, Oberti F, et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology. 2003;37(4):887–892. (In Russ.). DOI: https://doi.org/10.1053/jhep.2003.50118.
28. Bueverov AO. Possibilities of clinical application of ursodeoxycholic acid. Consilium Medicum. 2005; 7(6):460–463. (In Russ.). EDN: https://elibrary.ru/RFYJOZ.
29. Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? The Lancet. 1987;1(8537):834–836. DOI: https://doi.org/10.1016/s0140-6736(87)91610-2.
30. Mayevskaya MV. Ursodeoxycholic acid: Unique properties and clinical application. Medical Council. 2023; (8):96–105. (In Russ.). DOI: https://doi.org/10.21518/ms2023-136.
31. Beuers U. Drag insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nature Clinical Practice Gastroenterology & Hepatology. 2006;3(6):318–328. DOI: https://doi.org/10.1038/ncpgasthep0521.
32. Baranovsky AYu, Reichelson KL, Semenov NV, Solonitsin EG. Principles of treatment of cholestatic liver diseases. Lechashhij vrach. 2012;7:43. (In Russ.). EDN: https://elibrary.ru/SFPLNH.
33. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology. 2009;51(2):237–267. DOI: https://doi.org/10.1016/j.jhep.2009.04.009.
34. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology. 2017;67(1):145–172. DOI: https://doi.org/10.1016/j.jhep.2017.03.022.
35. Ivashkin VT, Shirokova EN, Maevskaya MV, Pavlov ChS, Shifrin OS, Maev IV, et al. Clinical recommendations of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver for the diagnosis and treatment of cholestasis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(2):41–57. (In Russ.). EDN: https://elibrary.ru/UIOSBN.
36. Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018;231:180–187. DOI: https://doi.org/10.1016/j.ejogrb.2018.10.041.
37. Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment in intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study). Medicine. 2016;95(40):e4949. DOI: https://doi.org/10.1097/MD.0000000000004949.
38. Evstifeeva SE, Shalnova SA, Kutsenko VA, Yarovaya EV, Balanova YuA, Imaeva AE, et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: Associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022; 21(9):3356. (In Russ.). DOI: https://doi.org/10.15829/1728-8800-2022-3356.
39. Pakhomova IG, Knorring GYu. Non-alcoholic fatty liver disease and cardiovascular pathology: Features of patient management on a clinical example. Experimental and Clinical Gastroenterology. 2022;(9):290–297. (In Russ.). DOI: https://doi.org/10.31146/1682–8658-ecg-205–9-290–297.
40. Maevskaya MV, Kotovskaya YuV, Ivashkin VT, Tkacheva ON, Troshina EA, Shestakova MV, et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. 2022;94(2):216–253. (In Russ.). DOI: https://doi.org/10.26442/00403660.2022.02.201363.
41. Maevskaya MV, Ivashkin VT, Ivashkin KV, Lunkov VD, Liusina EO, Zozula VN, et al. Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy. Terapevticheskii arkhiv. 2019;91(2):109–117. (In Russ.). DOI: https://doi.org/10.26442/00403660.2019.02.000122.
42. Wu P, Zhao J, Guo Y, Yu Y, Wu X, Xiao H. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochemical and Biophysical Research Communications. 2020;529(3):834–838. DOI: https://doi.org/10.1016/j.bbrc.2020.05.128.
43. Ozel Coskun BD, Yucesoy M, Gursoy S, Baskol M, Yurci A, Yagbasan A, et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. European Journal of Gastroenterology & Hepatology. 2015; 27(2):142–149. DOI: https://doi.org/10.1097/MEG.0000000000000264.
44. Martsevich SYu, Kutishenko NP, Drozdova LYu, Lerman OV, Nevzorova VA, Reznik II, et al. Ursodeoxycholic acid-enhanced efficiency and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases: The RACURS study. Terapevticheskii arkhiv. 2014;86(12):48–52. (In Russ.). DOI: https://doi.org/10.17116/terarkh2014861248–52.
45. Drapkina OM, Bueverova EL. Ursodeoxycholic acid: A therapeutic niche in an internist’s practice. Terapevticheskii arkhiv. 2015;87(4):84–90. (In Russ.). DOI: https://doi.org/10.17116/terarkh201587484-90.
46. Isaikina MA, Isaykina OYu, Trushina OYu. Metabolically associated fatty liver disease. Whatis the danger of a “safe” disease? Pathogenesis of cardiovascular complications. Lechaschi Vrach. 2025;(2):13–20. (In Russ.). DOI: https://doi.org/10.51793/OS.2025.28.2.002.
47. Patel VS, Mahmood SF, Bhatt KH, Khemkar RM, Jariwala DR, Harris B, et al. Ursodeoxycholic acid’s effectiveness in the management of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Euroasian Journal of Hepato-Gastroenterology. 2024;14(1):92–98. DOI: https://doi.org/10.5005/jp-journals-10018–1434.
48. Mayevskaya MV, Nadinskaia MYu, Lunkov VD, Pirogova IYu, Chesnokov EV, Kodzoeva KhB, et al. An effect of ursodeoxycholic acid on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease: Results of the USPEH study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22–29. (In Russ.). DOI: https://doi.org/10.22416/1382-4376-2019-29-6-22-29.
49. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arteriosclerosis, Thrombosis and Vascular Biology. 2005;25(10):2020–2030. DOI: https://doi.org/10.1161/01.ATV.0000178994.21828.a7.
50. Zvenigorodskaya LA, Mkrtumyan AM, Shinkin MV, Nilova TV, Petrakov AV. Metabolic tandem targets: Non-alcoholic fatty liver disease and type 2 diabetes mellitus. Russian Medical Journal. 2018;26(1–1):55–59. (In Russ.). EDN: https://elibrary.ru/YAIZSH.
51. Sánchez-García A, Sahebkar A, Simental-Mendía M, Simental-Mendía LE. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacological Research. 2018;135:144–149. DOI: https://doi.org/10.1016/j.phrs.2018.08.008.
52. Ivashkin VT, Maevskaya MV, Zharkova MS, Kotovskaya YuV, Tkacheva ON, Troshina EA, et al. Clinical guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology for the diagnosis and treatment of non-alcoholic fatty liver disease. Russian Journal of Gastroenterology, Hepatology, Proctology. 2022;32(4):104–140. (In Russ.). DOI: https://doi.org/10.22416/1382-4376-2022-32-4-104-140.
53. Oyama K, Shiota G, Ito H, Murawaki Y, Kawasaki H. Reduction on hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis. 2002;23(5):885–892. DOI: https://doi.org/10.1093/carcin/23.5.885.
54. Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S, et al. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(1):164–169. PMID: https://pubmed.gov/15668491.
55. Liu H, Xu H, Zhang W, Huang Y, Han G, Liang T, et al. Ursedeoxycholic acid induces apoptosin in hepatocellular carcinoma xenographic in mice. World Journal of Gastroenterology. 2015;21(36):10367–10374. DOI: https://doi.org/10.3748/wjg.v21.i36.10367.
56. Tadano T, Kanoh M, Kondoh H, Matsumoto M, Mimura K, Kanoh Y, et al. Kinetic analysis of bile acids in the feces of colorectal cancer patients by gas chromatography-mass spectrometry (GC–MS). Rinsho Byori. 2007;55(5):417–427. PMID: https://pubmed.gov/17593686.
57. Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al; Phoenix and Tucson Gastroenterologist Networks. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. Journal of the National Cancer Institute. 2005;97(11):846–853. DOI: https://doi.org/10.1093/jnci/dji144.
58. Singh S, Loftus EV, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. American Journal of Gastroenterology. 2013;108(9):1417–1425. DOI: https://doi.org/10.1038/ajg.2013.163.
59. Barrasa J, Olmo N, Lisarbe MA, Turnay J. Bile acids in the colon, from healthy by cytotoxic molecules. Toxicology in Vitro. 2013;27(2):964–977. DOI: https://doi.org/10.1016/j.tiv.2012.12.020.
60. Banerjee B, Shaheen NJ, Martines JA, Hsu C, Trowers E, Gibson BA, et al. Clinical study of ursodeoxycholic acid in Barrett’s esophagus patients. Cancer Prevention Research. 2016;9(7):528–533. DOI: https://doi.org/10.1158/1940-6207.capr-15–0276.
61. Kim YJ, Jeong SH, Kim EK, Kim EJ, Cho JH. Ursodeoxycholic acid suppresses epithelial-mesenchymal transition and cancer steam cell formation by reducing the levels of peroxiredoxin II and reactive oxygen species inpancreaticcancercells.OncologyReports.2017;38(6):3632–3638.DOI:https://doi.org/10.3892/or.2017.6045.
62. Reyzis AR. Ursodeoxycholic acid and cancer prevention. Medical Council. 2019;(14):39–43. (In Russ.). DOI: https://doi.org/10.21518/2079-701x-2019-14-39-43.
63. Wu YC, Chiu CF, Hsueh CT, Hsueh CT. The role of bile acids in cellular invasiveness of gastric cancer. Cancer Cell International. 2018;18:75. DOI: https://doi.org/10.1186/s12935-018-0569-0.
64. Pang L, Zhao X, Liu W, Deng J, Tan X, Qiu L. Anticancer effect of ursodeoxycholic acid in human oral squamous carcinoma HSC-3 cells through the caspases. Nutrients. 2015;7(5):3200–3218. DOI: https://doi.org/10.3390/nu7053200.
65. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin and DJ-1 in Caenorhabditis elegans. Journal of Biological Chemistry. 2005;280(52):42655–42668. DOI: https://doi.org/10.1074/jbc.M505910200.
66. Rodrigues CM, Spellman SR, Sola S, Grande AW, Linehan-Stieers C, Low WC, et al. Neuroprotection by a bile acid in an acute stroke model in the rat. Journal of Cerebral Blood Flow & Metabolism. 2002;22(4): 463–471. DOI: https://doi.org/10.1097/00004647-200204000-00010.
67. Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proceedings of the National Academy of Sciences. 2003;100(10):6087–6092. DOI: https://doi.org/10.1073/pnas.1031632100.
68. Payne T, Appleby M, Buckley E, van Gelder LMA, Mullish BH, Sassani M, et al. A double-blind, randomized placebo-controlled trial of ursodeoxycholic acid (UDCA) in Parkinson’s disease. Movement Disorders. 2023;38(8):1493–1502. DOI: https://doi.org/10.1002/mds.29450.
69. Qi H, Shen D, Jiang C, Wang H, Chang M. Ursodeoxycholic acid protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis in MPTP/MPP+-induced Parkinsons disease. Neuroscience Letters. 2021;741:135493. DOI: https://doi.org/10.1016/j.neulet.2020.135493.
70. Parry GJ, Rodrigues CM, Aranha MM, Hilbert SJ, Davey C, Kelkar P, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis. Clinical Neuropharmacology. 2010;33(1):17–21. DOI: https://doi.org/10.1097/WNF.0b013e3181c47569.
Рецензия
Для цитирования:
Ковалёва НБ. Урсодезоксихолевая кислота — многофункциональное средство в гастроэнтерологии. Уральский медицинский журнал. 2025;24(5):116-132. https://doi.org/10.52420/umj.24.5.116. EDN: YHXYLD
For citation:
Kovaleva NB. Ursodeoxycholic Acid is a Multifunctional Agent in Gastroenterology. Ural Medical Journal. 2025;24(5):116-132. (In Russ.) https://doi.org/10.52420/umj.24.5.116. EDN: YHXYLD
Просмотров:
17
Послать статью по эл. почте 